Service | Source | Final Application Due Date | Funding Available | Match Required |
---|---|---|---|---|
Health Care |
Federal
HHS |
01-28-2025 | N/A | No Match Required |
93.855 -- Allergy and Infectious Diseases Research
The purpose of this notice of funding opportunity (NOFO) is to support milestone-driven, early-stage translational research focused on drug discovery and development of novel therapeutics against select fungal pathogens including: Candida species, specifically Candida auris; Aspergillus fumigatus; Coccidioides; and Mucorales. This NOFO will use a milestone-driven, biphasic award mechanism. Transition to the R33 phase will depend on the successful completion of specific milestones during the R21 phase.
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
NIH Grants Information
grantsinfo@nih.gov
How would you rate your overall experience on our website?
How easy is it to find the information you need?
How do you rate the look & feel of our website?
How could we improve our website?